INS and Hypoglycemia: To our knowledge, this is the first study to evaluate effects to β-cell mass following such an extended period of insulin-induced hypoglycaemia using a well-controlled, standardized, and reproducible model with individual adjustment of doses, as opposed to insulin implants, and without any confounding factors potentially accompanying insulinomas; the hypoglycaemia was consistent throughout the eight weeks.